166 related articles for article (PubMed ID: 24252723)
1. HPLC method development, validation and impurity characterization for an antitumor Hsp90 inhibitor-PU-H71 (NSC 750424).
Liu M; Wang J; Wu X; Wang E; Baptista D; Scott B; Liu P
J Pharm Biomed Anal; 2014 Feb; 89():34-41. PubMed ID: 24252723
[TBL] [Abstract][Full Text] [Related]
2. HPLC method development, validation, and impurity characterization of a potent antitumor indenoisoquinoline, LMP776 (NSC 725776).
Wang J; Liu M; Yang C; Wu X; Wang E; Liu P
J Pharm Biomed Anal; 2016 May; 124():267-273. PubMed ID: 26970596
[TBL] [Abstract][Full Text] [Related]
3. HPLC method development, validation, and impurity characterization of a potent antitumor nucleoside, T-dCyd (NSC 764276).
Liu M; Wang J; Liu P
J Pharm Biomed Anal; 2016 Nov; 131():429-435. PubMed ID: 27661436
[TBL] [Abstract][Full Text] [Related]
4. Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2.
Gallerne C; Prola A; Lemaire C
Biochim Biophys Acta; 2013 Jun; 1833(6):1356-66. PubMed ID: 23485394
[TBL] [Abstract][Full Text] [Related]
5. The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1.
Usmani SZ; Bona RD; Chiosis G; Li Z
J Hematol Oncol; 2010 Oct; 3():40. PubMed ID: 20977755
[TBL] [Abstract][Full Text] [Related]
6. Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma.
Ambati SR; Lopes EC; Kosugi K; Mony U; Zehir A; Shah SK; Taldone T; Moreira AL; Meyers PA; Chiosis G; Moore MA
Mol Oncol; 2014 Mar; 8(2):323-36. PubMed ID: 24388362
[TBL] [Abstract][Full Text] [Related]
7. Radiosynthesis of the iodine-124 labeled Hsp90 inhibitor PU-H71.
Taldone T; Zatorska D; Ochiana SO; Smith-Jones P; Koziorowski J; Dunphy MP; Zanzonico P; Bolaender A; Lewis JS; Larson SM; Chiosis G; Pillarsetty NV
J Labelled Comp Radiopharm; 2016 Mar; 59(3):129-32. PubMed ID: 26806023
[TBL] [Abstract][Full Text] [Related]
8. PU-H71, a novel Hsp90 inhibitor, as a potential cancer-specific sensitizer to carbon-ion beam therapy.
Li HK; Matsumoto Y; Furusawa Y; Kamada T
J Radiat Res; 2016 Sep; 57(5):572-575. PubMed ID: 27242340
[TBL] [Abstract][Full Text] [Related]
9. The purine scaffold Hsp90 inhibitor PU-H71 sensitizes cancer cells to heavy ion radiation by inhibiting DNA repair by homologous recombination and non-homologous end joining.
Lee Y; Li HK; Masaoka A; Sunada S; Hirakawa H; Fujimori A; Nickoloff JA; Okayasu R
Radiother Oncol; 2016 Oct; 121(1):162-168. PubMed ID: 27666928
[TBL] [Abstract][Full Text] [Related]
10. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models.
Caldas-Lopes E; Cerchietti L; Ahn JH; Clement CC; Robles AI; Rodina A; Moulick K; Taldone T; Gozman A; Guo Y; Wu N; de Stanchina E; White J; Gross SS; Ma Y; Varticovski L; Melnick A; Chiosis G
Proc Natl Acad Sci U S A; 2009 May; 106(20):8368-73. PubMed ID: 19416831
[TBL] [Abstract][Full Text] [Related]
11. Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.
Rouhi A; Miller C; Grasedieck S; Reinhart S; Stolze B; Döhner H; Kuchenbauer F; Bullinger L; Fröhling S; Scholl C
Oncotarget; 2017 Jan; 8(5):7678-7690. PubMed ID: 28032595
[TBL] [Abstract][Full Text] [Related]
12. Validated stability indicating assay method of olaparib: LC-ESI-Q-TOF-MS/MS and NMR studies for characterization of its new hydrolytic and oxidative forced degradation products.
Thummar M; Kuswah BS; Samanthula G; Bulbake U; Gour J; Khan W
J Pharm Biomed Anal; 2018 Oct; 160():89-98. PubMed ID: 30075398
[TBL] [Abstract][Full Text] [Related]
13. Use of the hyphenated LC-MS/MS technique and NMR/IR spectroscopy for the identification of exemestane stress degradation products during the drug development.
Stolarczyk EU; Rosa A; Kubiszewski M; Zagrodzka J; Cybulski M; Kaczmarek Ł
Eur J Pharm Sci; 2017 Nov; 109():389-401. PubMed ID: 28865686
[TBL] [Abstract][Full Text] [Related]
14. Analytical method development, identification, and characterization of stress degradation products of idelalisib by ultrahigh-performance liquid chromatography with photodiode array and ultrahigh-performance liquid chromatography with electrospray ionization quadrupole time-of-flight mass spectrometry studies.
Mahesh M; Bali A; Gupta T
Rapid Commun Mass Spectrom; 2024 Jun; 38(11):e9745. PubMed ID: 38591150
[TBL] [Abstract][Full Text] [Related]
15. Dual Binding to Orthosteric and Allosteric Sites Enhances the Anticancer Activity of a TRAP1-Targeting Drug.
Hu S; Ferraro M; Thomas AP; Chung JM; Yoon NG; Seol JH; Kim S; Kim HU; An MY; Ok H; Jung HS; Ryu JH; Colombo G; Kang BH
J Med Chem; 2020 Mar; 63(6):2930-2940. PubMed ID: 32068404
[TBL] [Abstract][Full Text] [Related]
16. The novel HSP90 inhibitor, PU-H71, suppresses glial cell activation but weakly affects clinical signs of EAE.
Lisi L; McGuire S; Sharp A; Chiosis G; Navarra P; Feinstein DL; Dello Russo C
J Neuroimmunol; 2013 Feb; 255(1-2):1-7. PubMed ID: 23123171
[TBL] [Abstract][Full Text] [Related]
17. Forced degradation and impurity profiling: recent trends in analytical perspectives.
Jain D; Basniwal PK
J Pharm Biomed Anal; 2013 Dec; 86():11-35. PubMed ID: 23969330
[TBL] [Abstract][Full Text] [Related]
18. Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies.
Nayar U; Lu P; Goldstein RL; Vider J; Ballon G; Rodina A; Taldone T; Erdjument-Bromage H; Chomet M; Blasberg R; Melnick A; Cerchietti L; Chiosis G; Wang YL; Cesarman E
Blood; 2013 Oct; 122(16):2837-47. PubMed ID: 23943653
[TBL] [Abstract][Full Text] [Related]
19. HSP90 inhibitor PU-H71 increases radiosensitivity of breast cancer cells metastasized to visceral organs and alters the levels of inflammatory mediators.
Kale Ş; Korcum AF; Dündar E; Erin N
Naunyn Schmiedebergs Arch Pharmacol; 2020 Feb; 393(2):253-262. PubMed ID: 31522240
[TBL] [Abstract][Full Text] [Related]
20. LC-MS-MS Characterization of Forced Degradation Products of Fidarestat, a Novel Aldose Reductase Inhibitor: Development and Validation of a Stability-Indicating RP-HPLC Method.
Talluri MV; Khatoon L; Kalariya PD; Chavan BB; Ragampeta S
J Chromatogr Sci; 2015 Oct; 53(9):1588-96. PubMed ID: 26014964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
